| 摘要 |
The treatment, prevention or management of mantle cell lymphomas by administration of an immunomodulatory compound of the invention known as Revlimid<sup>(RTM)</sup> or lenalidomide are disclosed. The invention further relates to the use of this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy for the claimed treatment. Pharmaceutical compositions and single unit dosage forms suitable for use in the invention are also disclosed. |
